Trial Profile
A Double-blind, Placebo-controlled, Randomized Study in Rheumatoid Arthritis Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI5117 (Anti-IL-6)
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs WBP-216 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors AstraZeneca; Novo Nordisk
- 30 Jun 2013 Status changed from active, no longer recruiting to discontinued, according to an AstraZeneca pipeline.
- 25 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 May 2012 Actual initiation date (May 2012) added as reported by ClinicalTrials.gov.